1/23
05:06 am
asmb
Assembly Biosciences (NASDAQ:ASMB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Assembly Biosciences (NASDAQ:ASMB) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/24
06:43 am
asmb
With 32% ownership, Assembly Biosciences, Inc. (NASDAQ:ASMB) has piqued the interest of institutional investors [Yahoo! Finance]
Medium
Report
With 32% ownership, Assembly Biosciences, Inc. (NASDAQ:ASMB) has piqued the interest of institutional investors [Yahoo! Finance]
12/22
11:14 am
asmb
Assembly Biosciences (NASDAQ:ASMB) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Low
Report
Assembly Biosciences (NASDAQ:ASMB) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
12/8
04:05 pm
asmb
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Re
Low
Report
Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Re
11/20
10:59 am
asmb
Assembly Biosciences (NASDAQ:ASMB) was given a new $40.00 price target on by analysts at Mizuho.
Medium
Report
Assembly Biosciences (NASDAQ:ASMB) was given a new $40.00 price target on by analysts at Mizuho.